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1. INTRODUCTION {#mgg3848-sec-0005}
===============

Breast cancer (BC) is the most common cancer and the second leading cause of cancer‐related death in women worldwide (Coleman et al., [2011](#mgg3848-bib-0004){ref-type="ref"}; Jemal et al., [2011](#mgg3848-bib-0011){ref-type="ref"}). According to data released by the World Health Organization (WHO), the newly diagnosed cancer cases showed in 2012 accounted for 25.2% of all female primary cancer. In China, the number of new cases of BC was recently reported as 187,000, ranking first in the incidence rate of female cancers and posing a serious threat to the health and quality of life of Chinese women (Fitzmaurice et al., [2017](#mgg3848-bib-0005){ref-type="ref"}). It is widely known that multiple factors, especially genetic factors, contribute to BC susceptibility (Liu et al., [2017](#mgg3848-bib-0013){ref-type="ref"}). Recent studies showed, critical genetic and epigenetic alterations in genes encoding glycosyltansferases can cause pathologic changes in several disease states, including cancer (Palamar, Shearston, Dawson, Mateu‐Gelabert, & Ompad, [2016](#mgg3848-bib-0015){ref-type="ref"}).

Polypeptide *N*‐acetylgalactosaminyl transferases (*GALNTs*) are a large family of enzymes, which initiate the transfer of *N*‐acetylgalactosamine (*GalNAc*) from UDP‐GalNAc to the hydroxyl group of a serine or threonine residue have been associated with epithelial diseases (Chasman et al., [2008](#mgg3848-bib-0003){ref-type="ref"}; Hussain, Nasir, & Al‐Aama, [2013](#mgg3848-bib-0010){ref-type="ref"}; Tian et al., [2015](#mgg3848-bib-0023){ref-type="ref"}). The unusually large number of *GALNTs* is unique to O‐glycosylation and the multiplicity of conserved isoforms in metazoan evolution suggests a need for cell‐ or tissue‐specific isoforms (Bennett et al., [2012](#mgg3848-bib-0001){ref-type="ref"}). To date, 20 *GALNT* family members have been identified in humans, and these isozymes have been shown to exhibit differential but overlapping substrate specificities and cell type‐dependent expression patterns (Pratt et al., [2004](#mgg3848-bib-0019){ref-type="ref"}; Wandall et al., [1997](#mgg3848-bib-0024){ref-type="ref"}). Hence, the *GALNT* can be grouped into subfamilies. In subfamily Ib (*T2/T14/T16*)*, GALNT2* is the only well‐characterized isoform in the literature, but preliminary studies of these three enzymes show related functions (Bennett et al., [2012](#mgg3848-bib-0001){ref-type="ref"}). And, it has been reported that downregulation of *GALNT2* promoted cell proliferation, migration, invasion, and tumor metastasis (Liu et al., [2016](#mgg3848-bib-0014){ref-type="ref"}; Song et al., [2016](#mgg3848-bib-0020){ref-type="ref"}; Yao‐Ming et al., [2011](#mgg3848-bib-0026){ref-type="ref"}). *GALNT14* promotes lung‐specific BC metastasis by modulating self‐renewal and interaction with the lung microenvironment (Song et al., [2016](#mgg3848-bib-0020){ref-type="ref"}). Although, it has been identified that *GALNT16* significantly enriched for specific biological functions related to protein and lipid metabolism, insulin/IGF pathway‐protein kinase B signaling cascade, prolactin signaling pathway, and AMPK signaling pathways, the functional roles of *GALNT16* on BC progression are poorly understood (Gao et al., [2017](#mgg3848-bib-0007){ref-type="ref"}).

Thus, in order to assess the effect of single‐nucleotide polymorphisms (SNPs) in *GALNT16* on BC risk, we conducted a case--control study to explore the association between eight SNPs of *GALNT16* and BC risk in Chinese Han population.

2. METHODS {#mgg3848-sec-0006}
==========

2.1. Study subjects {#mgg3848-sec-0007}
-------------------

A case--control study was performed with 563 BC patients randomly recruited from Shaanxi Provincial Cancer Hospital. All patients, who were Han Chinese, had confirmed by histopathological analysis. The exclusion criteria included patients who were diagnosed with other types of cancers and/or underwent radiotherapy or chemotherapy. And the control group was comprised of 552 unrelated and age‐matched healthy individuals (without any underlying illnesses) from the same hospital. The methods were carried out in accordance with the World Medical Association Declaration of Helsinki, and the study was approved by the ethics committee of Shaanxi Provincial Cancer Hospital. After obtaining written informed consent, the data on clinical characteristics of patients, including tumor site, tumor size, lymph node metastasis, disease stage, Ki67 status, estrogen receptor (ER) status and progesterone receptor (PR) status, and human epidermal growth factor receptor (HER2) status, were collected from medical records.

2.2. Genotyping assay {#mgg3848-sec-0008}
---------------------

Peripheral blood of all subjects were collected in tubes containing EDTA and stored at −80°C. Then DNA was extracted using the GoldMag whole blood genomic DNA purification kit (GoldMag Co. Ltd., Xiʹan, China) according to the manufacturer\'s protocol, and the quantity of DNA was measured by spectrometry (NanoDrop 2000 spectrophotometer, Thermo Scientific, Waltham, MA). Eight SNPs in *GALNT16* with a minor allele frequency (MAF)\> 5% of the 1,000 Genomes Project data were selected in the present study. Agena MassARRAY Assay Design Software (version 3.0, Agena Bioscience, San Diego, CA) was used to design multiplexed SNP MassEXTEND assay. And Agena MassARRAY RS1000 was used to detect SNP genotyping (Fei et al., [2014](#mgg3848-bib-0012){ref-type="ref"}; Xia et al., [2014](#mgg3848-bib-0027){ref-type="ref"}, [2015](#mgg3848-bib-0028){ref-type="ref"}). Primers of the eight SNPs are listed in Table [1](#mgg3848-tbl-0001){ref-type="table"}. Data were analyzed with Agena Typer Software (version 4.0, Agena Bioscience, San Diego, CA).

###### 

Primers used for this study

  SNP          First PCRP                       Second PCRP                      UEP_DIR   UEP_SEQ
  ------------ -------------------------------- -------------------------------- --------- --------------------------------
  rs2105269    ACGTTGGATGCGGGCTGCTTCGACATTTTG   ACGTTGGATGCCAAAGAACAGAAAGCAGCG   R         AGCGTCTTGCACAGA
  rs61466740   ACGTTGGATGAGAAGTGGGCAGTCTCCACA   ACGTTGGATGTTCCAGGAAGACTCCTGGTG   R         ACGTTGGATGTTCCAGGAAGACTCCTGGTG
  rs72722128   ACGTTGGATGGTGCTTAACTCTACAGAGCC   ACGTTGGATGGGAACTGCATTGGCTTCTTG   F         cctcGCTGCACCCCTTAAT
  rs72625676   ACGTTGGATGTGTGGAGCGTAGGTCTCTG    ACGTTGGATGTGATCTGTCGCTTTGCTTGG   R         CGAGGTACGTTTGTCAC
  rs745781     ACGTTGGATGTAGAAACAGGATCTTGCTA    ACGTTGGATGGGCTCACACCTATAATCCCG   F         ggccGGAATTTGAGACCCGCCTAG
  rs1026385    ACGTTGGATGAACATAGAGGCCCTGAGCTG   ACGTTGGATGCTAGTCCTAGAGGGATGGTC   R         GGATCGCTGTGTGGAA
  rs1275678    ACGTTGGATGCACTTATGTGTTGTGGGACG   ACGTTGGATGAAGAATCCCTGCTCCTAACG   R         ggggaCTAACGTCTCAGAGACATA
  rs11623483   ACGTTGGATGTTCTTACAGTGGTCAGGCAG   ACGTTGGATGTTCTGCATCGCACTTTGCCC   R         CTTTGCCCCAGTCCC

Abbreviations: DIR, direction; PCRP, polymerase chain reaction primer; SEQ, sequence; SNP, single‐nucleotide polymorphism; UEP, unextended mini sequencing primer.
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2.3. Statistical analysis {#mgg3848-sec-0009}
-------------------------

SPSS software (version 18.0, Chicago, IL) was used for statistical analyses of data. The Student *t*test or chi‐squared test was used to examine the differences of basic parameters between two groups. Hardy--Weinberg equilibrium as well as the differences in allele frequencies between cases and controls were examined by chi‐squared test for each SNP. The BC risk associated with genotypes was estimated by odds ratios (OR) with 95% confidence intervals (CI) for five different genetic models. We further performed haplotype analysis and linkage disequilibrium. For all test, a two‐tailed *p*‐value \<.05 was considered statistically significant. HaploReg v4.1 (<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>) was conducted to predict the potential functions of the SNPs. And Gene Expression Profiling Interactive Analysis public database (GEPIA) (<http://gepia.cancer-pku.cn/>) was used to analyze *GALNT16* expression of BC and normal samples. Furthermore, we evaluated the relationship between prognostic significance of BC and the expression of *GALNT16* using Kaplan--Meier plotter (<http://kmplot.com/analysis/>).

3. RESULTS {#mgg3848-sec-0010}
==========

3.1. Characteristics of the study subjects {#mgg3848-sec-0011}
------------------------------------------

Our study included 563 patients with BC and 552 healthy controls. The clinical and demographic characteristic of BC patients and controls are shown in Table [2](#mgg3848-tbl-0002){ref-type="table"}. The cases and controls were matched by age (Student *t*test, *p =* .767). About 315 patients had a tumor size ≥2 cm and 275 patients had lymph node metastasis. Besides, patients with more than 10 percent of Ki67 are 365. The percentage of patients with PR‐, ER‐, and HER2‐positive status was 60.57%, 67.14%, and 48.49%, respectively.

###### 

Characteristics of breast cancer cases and healthy controls

  Characteristics            Cases (563)     Controls (552)   *p*‐value
  -------------------------- --------------- ---------------- -----------
  Age (years, mean ± *SD*)   52.05 ± 9.810   51.88 ± 9.849    .767
  Age, years                                                   
  \>51                       297             295               
  ≤51                        266             257               
  Tumor site                                                   
  Left                       226                               
  Right                      219                               
  Absence                    118                               
  Tumor size                                                   
  \<2 cm                     107                               
  ≥2 cm                      315                               
  Absence                    141                               
  LN metastasis                                                
  Negative                   260                               
  Positive                   275                               
  Absence                    28                                
  Stage                                                        
  I‐II                       365                               
  III‐IV                     162                               
  Absence                    36                                
  PR                                                           
  Negative                   212                               
  Positive                   341                               
  Absence                    10                                
  ER                                                           
  Negative                   161                               
  Positive                   378                               
  Absence                    24                                
  HER2 status                                                  
  Negative                   91                                
  Positive                   273                               
  Absence                    199                               
  Ki67                                                         
  \<10%                      132                               
  ≥10%                       365                               
  Absence                    66                                

Abbreviations: CI, confidence interval; ER, estrogen receptor; HER2: human epidermal growth factor receptor 2; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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3.2. Basic information and potential functions of the selected *GALNT16* SNPs {#mgg3848-sec-0012}
-----------------------------------------------------------------------------

The detailed information of eight SNPs in *GALNT16* was listed in Table [3](#mgg3848-tbl-0003){ref-type="table"}. For all SNPs, the MAFs were greater than 5% and the observed genotype frequencies complied with HWE in the control group. In addition, we annotate the functional elements of these selected SNPs using HaploRegv4.1. The results revealed that the SNPs in *GALNT16* were involved in the regulations related to selected eQTL hits, enhancer histones, DNAse, and motifs changed.

###### 

Basic information of candidate single‐nucleotide polymorphism (SNPs) in the study

  Gene         SNP         Role       Position   Case (563)   Control (552)   *p*‐HWE   HaploReg                                                                
  ------------ ----------- ---------- ---------- ------------ --------------- --------- ---------- ------------------------------------------------------------ --------------------
  *GALNT16*    rs2105269   intronic   69280517   A            0.3917          A         0.3702     .71                                                          Selected eQTL hits
  rs61466740   intronic    69289592   C          0.2504       C               0.2291    .90        Enhancer histone marks, DNAse                                
  rs72722128   intronic    69293300   A          0.1421       A               0.1506    .87        Enhancer histone marks, DNAse, Motifs changed                
  rs72625676   intronic    69307268   T          0.2709       T               0.2627    .91        Motifs changed                                               
  rs745781     intronic    69312014   C          0.2096       C               0.2114    .52        Enhancer histone marks, Motifs changed, Selected eQTL hits   
  rs1026385    intronic    69319346   G          0.0897       G               0.0833    .57        DNAse, Motifs changed                                        
  rs1275678    intronic    69335147   A          0.1012       A               0.1205    .69        Enhancer histone marks, DNAse                                
  rs11623483   intronic    69345012   A          0.2651       A               0.2840    .92        Enhancer histone marks, DNAse, Motifs changed                

Abbreviations: HWE, Hardy--Weinberg equilibrium; MA, minor allele; MAF, minor allele frequency; SNPs, single‐nucleotide polymorphism.
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3.3. Association of *GALNT16* SNPs with breast cancer susceptibility {#mgg3848-sec-0013}
--------------------------------------------------------------------

The genotypic and allelic frequencies of *GALNT16* rs2105269, rs61466740, rs72722128, rs72625676, rs745781, rs1026385, rs1275678, and rs11623483 in cases and controls are shown in Table [4](#mgg3848-tbl-0004){ref-type="table"}. We evaluated their associations with risk of BC by chi‐squared test and OR and five genetic models (codominant, dominant, recessive, additive, and allele) were applied to assess the potential association by logistic regression adjusted for age (Zhou et al., [2014](#mgg3848-bib-0029){ref-type="ref"}). However, we did not observe any significant association between the *GALNT16* polymorphisms and BC risk in all genetic models.

###### 

Frequencies of *GALNT16* gene alleles and genotypes of BC patients and controls

  Polymorphism   Genotype         Case             Control              OR (95% CI)          *p*‐value
  -------------- ---------------- ---------------- -------------------- -------------------- -----------
  rs2105269                                                                                   
  Codominant     AA               89 (15.8%)       73 (13.25%)          1.25 (0.87--1.791)   .237
  AG             263 (46.71%)     262 (47.55%)     1.02 (0.79--1.32)    .875                 
  GG             211 (37.48%)     216 (39.20%)     1                                         
  Dominant       AA‐AG            352 (62.52%)     335 (60.80%)         1.07 (0.84--1.36）   .586
  GG             211 (37.48%)     216 (39.20%)     1                                         
  Recessive      AA               89 (15.80%)      73 (13.25%)          1.23 (0.88--1.72）   .223
  AG‐GG          474 (84.19%)     478 (86.75%)     1                                         
  llele          A                441 (39.17%)     408 (37.02%)         1.10 (0.92--1.30）   .298
  G              685 (60.83%)     694 (62.98%)     1                                         
  Additive                                                              1.09 (0.92--1.30）   .312
  rs61466740                                                                                  
  Codominant     CC               35 (6.22%)       28 (5.10%)           1.29 (0.77--2.17)    .337
  CT             212 (37.66%)     196 (35.64%)     1.12 (0.87--1.43)    .379                 
  TT             316 (56.13%)     326 (59.27%)     1                                         
  Dominant       CC‐CT            247 (43.87%)     224 (40.73%)         1.14 (0.90--1.45）   .284
  TT             316 (56.13%)     326 (59.27%)     1                                         
  Recessive      CC               35 (6.21%)       28 (5.10%)           1.23 (0.74--2.06）   .419
  CT‐TT          528 (93.78%)     522 (94.91%)     1                                         
  Allele         C                282 (25.04%)     252 (22.91%)         1.12 (0.93--1.37）   .238
  T              844 (74.96%)     848 (77.09%)     1                                         
  Additive                                                              1.13 (0.93--1.37）   .234
  rs72722128                                                                                  
  Codominant     AA               11 (1.95%)       13 (2.36%)           0.81 (0.36--1.83)    .612
  AG             138 (24.51%)     140 (25.40%)     0.94 (0.72--1.23)    .654                 
  GG             414 (73.53%)     398 (72.36%)     1                                         
  Dominant       AA‐AG            149 (26.47%)     153 (27.77%)         0.93 (0.71--1.21）   .583
  GG             414 (73.53%)     398 (72.23%)     1                                         
  Recessive      AA               11 (1.95%)       13 (2.36%)           0.93 (0.73--1.17）   .533
  AG‐GG          552 (98.05%)     538 (97.64%)     1                                         
  Allele         A                160 (14.21%)     166 (15.06%)         0.93 (0.74--1.18）   .568
  G              966 (85.79%)     936 (84.94%)     1                                         
  Additive                                                              0.82 (0.37--1.85）   .639
  rs72625676                                                                                  
  Codominant     TT               38 (6.75%)       37 (6.73%)           1.04 (0.64--1.67)    .887
  TC             229 (40.67%)     215 (39.09%)     1.07 (0.84--1.37)    .569                 
  CC             296 (52.58%)     298 (54.18%)     1                                         
  Dominant       TT‐TC            267 (47.42%)     252 (45.82%)         1.07 (0.84--1.35）   .581
  CC             296 (52.58%)     298 (54.18%)     1                                         
  Recessive      TT               38 (6.75%)       37 (6.73%)           1.00 (0.63--1.61）   .986
  TC‐CC          525 (93.25%)     513 (93.27%)     1                                         
  Allele         T                305 (27.09%)     289 (26.27%)         1.04 (0.86--1.26）   .664
  C              821 (72.91%)     811 (73.73%)     1                                         
  Additive                                                              1.05 (0.86--1.26）   .652
  rs745781                                                                                    
  Codominant     CC               25 (4.44%)       27 (4.90%)           0.91 (0.52--1.59)    .734
  CG             186 (33.04%)     179 (32.55%)     1.01 (0.78--1.30)    .930                 
  GG             352 (62.52%)     345 (62.73%)     1                                         
  Dominant       CC‐CG            211 (37.48%)     206 (37.39%)         1.00 (0.78--1.27）   .985
  GG             352 (62.52%)     345 (62.61%)     1                                         
  Recessive      CC               25 (4.44%)       27 (4.90%)           0.90 (0.52--1.58）   .720
  CG‐GG          538 (95.56%)     524 (95.10%)     1                                         
  Allele         C                236 (20.96%)     233 (21.14%)         0.99 (0.81--1.21）   .915
  G              890 (79.04%)     869 (78.86%)     1                                         
  Additive                                                              0.99 (0.80--1.21）   .884
  rs1026385                                                                                   
  Codominant     GG               4 (0.71%)        5 (0.91%)            0.80 (0.21--3.02)    .746
  GA             93 (16.52%)      82 (14.86%)      1.14 (0.82--1.57)    .442                 
  AA             466 (82.77%)     465 (84.24%)     1                                         
  Dominant       GG‐GA            97 (17.23%)      87 (15.76%)          1.12 (0.81--1.53）   .496
  AA             466 (82.77%)     465 (84.24%)     1                                         
  Recessive      GG               4 (0.71%)        5 (0.91%)            0.79 (0.21--2.95）   .724
  GA‐AA          559 (99.29%)     547 (99.09%)     1                                         
  Allele         G                101 (8.97%)      92 (8.33%)           1.08 (0.81--1.46）   .593
  A              1,025 (91.03%)   1,012 (91.67%)   1                                         
  Additive                                                              1.01 (0.81--1.46）   .579
  rs1275678                                                                                   
  Codominant     AA               5 (0.89%)        9 (1.63%)            0.53 (0.17--1.58）   .253
  AC             104 (18.47%)     115 (20.83%)     0.85 (0.64--1.15）   .296                 
  CC             454 (80.64%)     428 (77.54%)     1                                         
  Dominant       AA‐AC            109 (19.36%)     124 (22.46%)         0.54 (0.18--1.63）   .277
  CC             454 (80.64%)     428 (77.54%)     1                                         
  Recessive      AA               5 (0.89%)        9 (1.63%)            0.82 (0.63--1.08）   .150
  AC‐CC          558 (99.11%)     543 (98.37%)     1                                         
  Allele         A                114 (10.12%)     133 (12.05%)         0.82 (0.63--1.07）   .148
  C              1,012 (89.88%)   971 (87.95%)     1                                         
  Additive                                                              0.82 (0.63--1.08）   .153
  rs11623483                                                                                  
  Codominant     AA               41 (7.30%)       45 (8.17%)           0.85 (0.54--1.33）   .475
  AG             216 (38.43%)     223 (40.47%)     0.89 (0.70--1.15）   .384                 
  GG             305 (54.27%)     283 (51.36%)     1                                         
  Dominant       AA‐AG            257 (45.73%)     268 (48.64%)         0.89 (0.70--1.12）   .323
  GG             305 (54.27%)     283 (51.36%)     1                                         
  Recessive      AA               41 (7.30%)       45 (8.17%)           0.89 (0.57--1.38）   .600
  AG‐GG          521 (92.70%)     506 (91.83%)     1                                         
  Allele         A                298 (26.51%)     313 (28.40%)         0.91 (0.75--1.10)    .317
  G              826 (73.49%)     789 (71.60%)     1                                         
  Additive                                                              0.91 (0.76--1.01）   .318

All results are adjusted for age.

Abbreviations: BC, breast cancer; CI, confidence interval; OR, odds ratio.
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3.4. Stratified analysis of *GALNT16* polymorphisms and BC risk {#mgg3848-sec-0014}
---------------------------------------------------------------

Then we performed a subgroup analysis regarding the effect of *GALNT16* polymorphisms, and rs2105269, rs72625676, and rs1275678 polymorphisms on BC according to age are displayed in Table [5](#mgg3848-tbl-0005){ref-type="table"}. The results indicated that rs2105269 was associated with increased BC risk in the women with age ≤51 (codominant model: OR = 2.16, 95% CI = 1.25--3.17, *p =* .006; recessive model: OR = 2.08, 95% CI = 1.24--3.49, *p* = .005; additive model: OR = 1.35, 95% CI = 1.05--1.73, *p* = .018; and allele model: OR = 1.38, 95% CI = 1.07--1.79, *p* = .012). Furthermore, compared with the wild genotype of rs72625676, we found a significantly increased risk of BC associated with the variant genotypes in two models (codominant model: OR = 2.30, 95% CI = 1.05--5.03, *p* = .038; recessive model: OR = 2.27, 95% CI = 1.05--4.89, *p* = .037) for the women whose ages are no more than 51. Nevertheless, rs1275678 had relationship with significantly decreasing the risk of BC in the subgroups of age \>51 for genetic models (codominant model: OR = 0.60, 95% CI = 0.40--0.91, *p* = .017; dominant model: OR = 0.62, 95% CI = 0.41--0.92, *p* = .019; additive model: OR = 0.66, 95% CI = 0.46--0.96, *p* = .030; and allele model: OR = 0.66, 95% CI = 0.45--0.96, *p* = .029).

###### 

Stratified analysis of polymorphisms in *GALNT16* on BC risk by age

  SNP          Model        Allele/Genotype     Age \>51 (297) versus controls (295)   Age ≤51 (266) versus controls (257)                       
  ------------ ------------ ------------------- -------------------------------------- ------------------------------------- ------------------- ----------
  rs2105269    Codominant   AA                  0.78 (0.47--1.29)                      .326                                  2.16 (1.25--3.74)   **.006**
               AG           0.95 (0.66--1.36)   .783                                   1.08 (0.74--1.56)                     .698                
               GG           1                                                          1                                                         
  Dominant     AA‐AG        0.91 (0.65--1.28)   .583                                   1.27 (0.90--1.80)                     .172                
               GG           1                                                          1                                                         
  Recessive    AA           0.80 (0.51--1.26)   .338                                   2.08 (1.24--3.49)                     **.005**            
               AG‐GG        1                                                          1                                                         
  Allele       A            0.90 (0.72--1.14)   .393                                   1.38 (1.07--1.79)                     **.012**            
               G            1                                                          1                                                         
  Additive                  0.90 (0.70--1.14)   .371                                   1.35 (1.05--1.73)                     **.018**            
  rs72625676   Codominant   TT                  0.59 (0.30--1.13)                      .112                                  2.30 (1.05--5.03)   **.038**
               TC           1.10 (0.79--1.55)   .562                                   1.04 (0.72--1.48)                     .853                
               CC           1                                                          1                                                         
  Dominant     TT‐TC        1.01 (0.73--1.39)   .967                                   1.15 (0.81--1.62)                     .430                
               CC           1                                                          1                                                         
  Recessive    TT           0.56 (0.29--1.06)   .076                                   2.27 (1.05--4.89)                     **.037**            
               TC‐CC        1                                                          1                                                         
  Allele       T            0.91 (0.71--1.17)   .466                                   1.23 (0.93--1.63)                     .145                
               C            1                                                          1                                                         
  Additive                  0.91 (0.70--1.18)   .477                                   1.24 (0.93--1.64)                     .140                
  rs1275678    Codominant   AA                  0.92 (0.18--4.61)                      .917                                  0.32 (0.06--1.63)   .172
               AC           0.60 (0.40--0.91)   **.017**                               1.26 (0.81--1.95)                     .301                
               CC           1                                                          1                                                         
  Dominant     AA‐AC        0.62 (0.41--0.92)   **.019**                               1.15 (0.75--1.75)                     .521                
               CC           1                                                          1                                                         
  Recessive    AA           1.01 (0.20--5.06)   .989                                   0.31 (0.06--1.55)                     .154                
               AC‐CC        1                                                          1                                                         
  Allele       A            0.66 (0.46--0.96)   **.029**                               1.04 (0.71--1.52)                     .847                
               C            1                                                          1                                                         
  Additive                  0.66 (0.45--0.96)   **.030**                               1.03 (0.71--1.51)                     .865                

*p*‐value \< .05 was shown in bold.

Abbreviations: BC, breast cancer; CI, confidence interval; OR, odds ratio.
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3.5. Haplotype analysis of *GALNT16* polymorphisms and BC risk {#mgg3848-sec-0015}
--------------------------------------------------------------

As shown in Table [S1](#mgg3848-sup-0005){ref-type="supplementary-material"}, we did not find significant association between *GALNT16* haplotype and BC risk. We observed three blocks, they are block 1 (rs61466740 and rs72722128), block 2 (rs72625676, rs745781, and rs1026385), and block 3 (rs1275678 and rs11623483) (Figure [1](#mgg3848-fig-0001){ref-type="fig"}). We further conducted haplotype analysis in age subgroups. In the subgroup of age \>51, we found two blocks (block 1: rs61466740 and rs72722128, block 2: rs72625676 and rs745781) (Table [S2](#mgg3848-sup-0005){ref-type="supplementary-material"} and Figure [S1](#mgg3848-sup-0001){ref-type="supplementary-material"}). For the individuals younger than 51 years old, C~rs72625676~G~rs745781~A~rs1026385~ haplotype increased BC risk (*p* = .046) (Table [S3](#mgg3848-sup-0005){ref-type="supplementary-material"}). As shown in Figure [S2](#mgg3848-sup-0002){ref-type="supplementary-material"}, We observed two blocks (block 1: rs72625676, rs745781, and rs1026385; block 2: rs1275678 and rs11623483).

![Haplotype block map for the *GALNT16* gene polymorphisms. Block 1 includes rs61466740 and rs72722128. Block 2 includes rs72625676, rs745781, and rs1026385. Block 3 includes rs1275678 and rs1162343. The numbers inside the diamonds indicate the D′ for pairwise analyses](MGG3-7-e848-g001){#mgg3848-fig-0001}

3.6. Relationship between *GALNT16* SNPs and clinical features of BC patients {#mgg3848-sec-0016}
-----------------------------------------------------------------------------

In order to identify the effect of *GALNT16* SNPs on different clinical characteristics of BC patients, we then analyzed the relationships between *GALNT16* polymorphisms and a series of clinicopatholoical parameters, such as tumor site/size, lymph node metastasis, and hormonal receptor status. As shown in Table [6](#mgg3848-tbl-0006){ref-type="table"}, we found that the mutational genotype frequency of rs2105269 was significantly higher in patients with tumor size greater than 2cm (homozygote model: OR = 2.01, 95% CI = 1.00--4.03; heterozygote model: OR = 1.66, 95% CI = 1.03--2.69; dominant model: OR = 1.74, 95% CI = 1.11--2.73; additive model: OR = 1.48, 95% CI = 1.07--2.06; and allele model: OR = 1.47, 95% CI = 1.06--2.03) and lymph node metastasis (heterozygote model: OR = 1.59, 95% CI = 1.10--2.32). However, no significant association was detected in other clinical parameters of BC patients.

###### 

Associations between the *GALNT16* rs2105269 polymorphism and clinical characteristics of BC patients

  Variables       OR(95% CI)                                                                                                           
  --------------- ----------------------- ----------------------- ----------------------- -------------------- ----------------------- -----------------------
  Tumor site                                                                                                                            
  Left            1.53 (0.96--2.43)       1.07 (0.76--1.51)       1.17 (0.85--1.62)       1.47 (0.96--2.24)    1.20 (0.96--1.51)       1.19 (0.95--1.49)
  Right           1.04 (0.64--1.71)       1.00 (0.71--1.4)        1.01 (0.73--1.39)       1.04 (0.66--1.65)    1.01 (0.80--1.28)       1.02 (0.81--1.28)
  Tumor size                                                                                                                            
  \<2 cm          1.00                                                                                                                  
  ≥2 cm           **2.01 (1.00--4.03)**   **1.66 (1.03--2.69)**   **1.74 (1.11--2.73)**   1.53 (0.80--2.92)    **1.48 (1.07--2.06)**   **1.47 (1.06--2.03)**
  LN metastasis                                                                                                                         
  Negative        1.00                                                                                                                  
  Positive        0.86 (0.51--1.45)       **1.59 (1.10--2.32)**   1.3730.96--1.95)        0.66 (0.41--1.08)    1.05 (0.82--1.34)       1.05 (0.82--1.34)
  Stage                                                                                                                                 
  I‐II            1.00                                                                                                                  
  III‐IV          1.03 (0.59--1.81)       1.06 (0.70--1.59)       1.05 (0.71--1.55)       1.00 (0.60--1.67)    1.02 (0.78--1.34)       1.03 (0.79--1.34)
  PR                                                                                                                                    
  Negative        1.00                                                                                                                  
  Positive        0.96 (0.57--1.62)       0.86 (0.59--1.25)       0.88 (0.62--1.26)       1.05 (0.65--1.69)    0.95 (0.74--1.22)       0.95 (0.74--1.22)
  ER                                                                                                                                    
  Negative        1.00                                                                                                                  
  Positive        1.14 (0.64--2.01)       1.04 (0.69--1.55)       1.06 (0.72--1.55)       1.12 (0.66--1.88)    1.06 (0.81--1.38)       1.06 (0.81--1.38)
  HER2 status                                                                                                                           
  Negative        1.00                                                                                                                  
  Positive        0.94 (0.45--1.97)       1.01 (0.60--1.70)       0.99 (0.61--1.62)       0.93 (0.47--1.85）   0.98 (0.69--1.39)       0.98 (0.69--1.38)
  Ki67                                                                                                                                  
  \<10%           1.00                                                                                                                  
  ≥10%            0.93 (0.51--1.68)       1.05 (0.68--1.64)       1.02 (0.67--1.54)       0.90 (0.52--1.55)    0.98 (0.74--1.31)       0.99 (0.74--1.32)

OR of significant association is presented in bold.

Abbreviations: BC, breast cancer; CI, confidence interval; ER, estrogen receptor; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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3.7. Bioinformatics analysis of *GALNT16* expression and prognosis {#mgg3848-sec-0017}
------------------------------------------------------------------

Based on GEPIA dataset, *GALNT16* presented higher expression in BC tissues than in normal tissues (Figure [S3](#mgg3848-sup-0003){ref-type="supplementary-material"}). Then, the significantly association between *GALNT16* expression and BC prognosis was found according to Kaplan--Meier plotter (hazard ratio = 0.64; 95% CI = 0.55--0.75; *p* = 1.7e‐08; Figure [S4](#mgg3848-sup-0004){ref-type="supplementary-material"}).

4. DISCUSSION {#mgg3848-sec-0018}
=============

Glycosylation is a posttranslational modification and is associated with various physiologic events. The aberrant expression of glycosyltransferase and the immature glycan structure of proteins and lipids are observed in the development and progression of cancers (Brockhausen, [1999](#mgg3848-bib-0002){ref-type="ref"}; Fuster & Esko, [2005](#mgg3848-bib-0006){ref-type="ref"}; Park, Katagiri, Chung, Kijima, & Nakamura, [2011](#mgg3848-bib-0016){ref-type="ref"}; Park et al., [2010](#mgg3848-bib-0017){ref-type="ref"}; Potapenko et al., [2010](#mgg3848-bib-0018){ref-type="ref"}). Abnormalities of the glycan structure of glycoproteins are frequently observed in BC cells (Fuster & Esko, [2005](#mgg3848-bib-0006){ref-type="ref"}; Park et al., [2011](#mgg3848-bib-0016){ref-type="ref"}, [2010](#mgg3848-bib-0017){ref-type="ref"}). In particular, the oncogenic roles of some cancer‐specific glycosyltransferases had been identified and characterized previously. To further investigate the oncogenic role of aberrant glycosyltransferase expression, we attempted to identify the association of *GALNT16* polymorphisms and BC risk. In this case--control study, we successfully genotyped eight SNPs in the *GALNT16* and found that *GALNT16* polymorphisms are associated with BC susceptibility in the Chinese and may be involved in tumor progression.

*GALNT16* (Polypeptide N‐acetylgalactosaminyltransferase 16) is a protein coding gene, which catalyzes the initial reaction in O‐linked oligosaccharide biosynthesis and transfers an N‐acetyl‐D‐galactosamine residue to a serine or threonine residue on the protein receptor. An important paralog of this gene is *GALNT2*. Recent studies reported that *GALNT2* genetic polymorphisms were associated several cancers, including gastric adenocarcinoma, neuroblastoma, ovarian cancer, and BC (Gill et al., [2013](#mgg3848-bib-0008){ref-type="ref"}; Liu et al., [2016](#mgg3848-bib-0014){ref-type="ref"}; Terry et al., [2010](#mgg3848-bib-0022){ref-type="ref"}; Wan‐Ling et al., [2014](#mgg3848-bib-0025){ref-type="ref"}). Although the overexpression of *GALNT2* involved in the cell growth of BC, only few researches are done on this field (Taisuke et al., [2014](#mgg3848-bib-0021){ref-type="ref"}). Likewise, the overexpression of *GALNT14* plays a critical role in cell migration, invasion, and proliferation of BC by stimulating the epithelial mesenchymal transition of BC cells (Huanna et al., [2015](#mgg3848-bib-0009){ref-type="ref"}). As Ib subfamily, *GALNT16* shares the same intron numbers (with minor variations in introns positions) with *GALNT2* and *GALNT14*. The currently available data on the enzymatic functions of GALNTs support the proposed subfamily classification. Moreover, due to the high sequence similarity of Ib subfamily, similar biological functions can be postulated.

Our study focused on the relationship of *GALNT16* and BC risk in Chinese Han populations and found that rs2105269 and rs72625676 polymorphisms were associated with an increased BC risk in the women with age ≤51, and a relationship was found between the rs1275678 and BC subjects with age \>51, which may predict rs1275678 is a protective factor. Furthermore, the A allele of rs2105269 was related with a larger size of tumor (≥2cm). It was also correlated with lymph node metastasis, indicating that patients with A allele of rs2105269 are more likely to have a worse prognosis. Our results update the previous studies, suggesting the critical to some SNPs could affect the susceptibility of *GALNT16*.

Some limitations could not be ignored in the study. First, choosing bias inevitably exists as this is a hospital‐based, single‐center study. Second, we did not analyze the impact of other risk factors such as lifestyle, family history, and menopausal status because of a lack of such data from both patients and controls. As our case--control study is the first research to elucidate on the association of *GALNT16* polymorphisms with BC risk, large sample size and further confirmation in other ethnic populations are needed.

5. CONCLUSION {#mgg3848-sec-0019}
=============

In summary, this case--control study indicates that the *GALNT16* polymorphisms are associated with BC susceptibility in the Chinese population and may be involved in tumor progression. Further functional studies and large population‐based prospective studies are required to provide accurate evidence about the influence of *GALNT16* variants on BC.
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